EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in Europe

Sneha S Kelkar, Vimalanand S Prabhu, Jingchuan Zhang, Yoscar M Ogando, Kyle Roney, Rishi P Verma, Nicola Miles, Christian Marth

Archives of Gynecology and Obstetrics · 18.04.2024 · 309 (6) · 2833-2841

DOI: 10.1007/s00404-024-07504-3 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Archives of Gynecology and Obstetrics, online erschienen am 18.04.2024. Verfasst von Sneha S Kelkar und 7 weiteren Autor:innen. Beteiligte Einrichtung: OPEN Health, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Microsatellite Instability, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck, Eisai Incorporated.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To assess the real-world prevalence of microsatellite instability (MSI)/mismatch repair (MMR) testing and related tumor status in recurrent/advanced endometrial cancer patients in Europe.

Methods

Data were from two multi-center, retrospective patient chart review studies conducted in the United Kingdom, Germany, Italy, France and Spain: The Endometrial Cancer Health Outcomes-Europe-First-Line (ECHO-EU-1L) study and the ECHO-EU-Second-Line (ECHO-EU-2L) study. ECHO-EU-1L included recurrent/advanced endometrial cancer patients who received first-line systemic therapy between 1/JUN/2016 and 31/MAR/2020 after recurrent/advanced diagnosis. ECHO-EU-2L included patients with recurrent/advanced endometrial cancer who progressed between 1/JUN/2016 and 30/JUN/2019 following prior first-line systemic therapy. Data collected included patient demographics, MSI/MMR tumor testing and results, and clinical/treatment characteristics.

Results

ECHO-EU-1L included 242 first-line patients and ECHO-EU-2L included 475 s-line patients. For all patients, median age at recurrent/advanced diagnosis was 69 years, roughly half had endometrioid carcinoma histology and over 75% had Stage IIIB-IV disease at initial diagnosis. The prevalence of MSI/MMR testing in the first-line and second-line cohorts was similar (36.4 and 34.9%, respectively). Among those tested, a majority had non-MSI-high/MMR proficient tumors (80.7 and 74.7% among first- and second-line patients, respectively). About 15% had MSI-high/MMR deficient tumors in both cohorts, and a few patients had discordant results (3.4 and 10.8% among first- and second-line patients, respectively).

Conclusion

Prior to the approvals of biomarker-directed therapies for recurrent/advanced endometrial cancer patients in Europe, there were low MSI/MMR testing rates for these patients of just over one-third. Given the availability of biomarker-directed therapies, increased MSI/MMR testing may help inform treatment decisions for recurrent/advanced endometrial cancer patients in Europe.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsMicrosatellite InstabilityNeoplasm Recurrence, LocalHumansFemaleAgedRetrospective StudiesEuropeMiddle AgedPrevalenceDNA Mismatch RepairNeoplasm StagingAged, 80 and overCarcinoma, Endometrioid

Stichwörter der Autor:innen

BiomarkersGynecologyMismatch repairOncologyRecurrentRetrospective

Autor:innen und Institutionen

  • OPEN Health, Bethesda, MD, USA.
  • Merck & Co., Inc., 126 East Lincoln Ave, P.O. Box 2000, Rahway, NJ, 07065, USA. vimalanand.prabhu@merck.com.
  • Eisai Inc., Nutley, NJ, USA.
  • M3 (EU) Ltd., Abingdon, UK.
  • Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria.

Förderung

  • Merck
  • Eisai Incorporated

Zitieren

APA

Kelkar, S. S., Prabhu, V. S., Zhang, J., Ogando, Y. M., Roney, K., Verma, R. P., Miles, N., & Marth, C. (2024). Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in Europe. Archives of Gynecology and Obstetrics, 309(6), 2833-2841. https://doi.org/10.1007/s00404-024-07504-3

Vancouver

Kelkar SS, Prabhu VS, Zhang J, Ogando YM, Roney K, Verma RP, et al. Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in Europe. Archives of Gynecology and Obstetrics. 2024;309(6):2833-2841. doi:10.1007/s00404-024-07504-3

BibTeX
@article{Kelkar2024,
  author = {Kelkar, Sneha S and Prabhu, Vimalanand S and Zhang, Jingchuan and Ogando, Yoscar M and Roney, Kyle and Verma, Rishi P and Miles, Nicola and Marth, Christian},
  title = {Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in Europe},
  journal = {Archives of Gynecology and Obstetrics},
  year = {2024},
  volume = {309},
  number = {6},
  pages = {2833--2841},
  doi = {10.1007/s00404-024-07504-3}
}
Kostenlos starten →